Tonix Pharmaceuticals has reiterated its commitment to developing its live attenuated virus vaccine, TNX-801, as a potential solution to prevent mpox and other infectious diseases. TNX-801, based on horsepox virus, offers advantages like single-dose administration and improved tolerability compared to older vaccinia vaccines.